DOCSLIB.ORG

Mobilization Failure in Hematopoietic Stem Cell Transplantation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mobilization Failure in Hematopoietic Stem Cell Transplantation MOBILIZATION FAILURE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION Siret Ratip Department of Haematology, Acıbadem University School of Medicine, İstanbuy, Turkey G-CSF–based mobilization regimens have a plantations, G-CSF is given at 10 μg/kg per day 5%-30% failure rate among healthy donors and subcutaneously with apheresis beginning on the patients, but the rate can be up to 60% in high- fifth day until the yield target is reached. There is risk patients such as those exposed to fludarabine. no evidence that twice daily administration gives a Poor mobilization has significant consequences for higher yield than once-daily (4). the patient with potential loss of the transplant as a treatment option. Repeated attempts at mobiliza- Combining G-CSF with chemotherapy for tion increase resource use, morbidity, and patient/ mobilization donor inconvenience. Therefore, there is much Combining G-CSF with chemotherapy achieves interest in the prevention and salvage of mobiliza- both mobilization and antitumor activity and has tion failure with novel strategies. been shown to result in a higher CD34+ cell yield than G-CSF alone (5). Regimens such as cyclo- The role of CD34+ cell dose in phosphamide, doxorubicin, vincristine, and pred- haematopoeitic stem cell transplantation nisone/dexamethasone, high-dose cytarabine, and Benefits of rapid recovery in HSCT are reduced cisplatin or cyclophosphamide 1-5 g/m2 have been hospitalization, blood product usage, and infec- used with G-CSF which is commenced 1-3 days tions. Minimum threshold of CD34+ cell dose for following cyclophosphamide. Apheresis is usually autologous transplantation is currently 2 × 106 started when leukocyte count reaches > 2 × 109/L. CD34+ cells/kg body weight (BW) (1). Many cen- Benefit of higher mobilization yield with high- ters use a minimum of 3 × 106 CD34+ cells/kg BW er doses of chemotherapy needs to be balanced for myeloablative and nonmyeloablative allogeneic against more red cell and platelet transfusions, and matched unrelated transplantations. Further- and, frequently, hospitalization for febrile neu- more, > 5 × 106 CD34+ cells/kg BW is associated tropenia, and it is more justified when significant with even lower resource use and faster and more antitumor effects exist (6). A prospective study that complete platelet engraftment and better survival compared 5 versus 10 μg/kg per day after stan- in allogeneic transplantations (2). It is probable dard chemotherapy was inconclusive (7). G-CSF 5 that higher cell doses (eg, ≥ 5 × 106 CD34+ cells/ μg/kg per day is used in most units for combined kg BW) may be similarly beneficial in mismatched G-CSF/chemotherapy mobilization. transplantations. In haplotype mismatched trans- plantations doses of ≥ 10 × 106 CD34+ cells/kg BW Pegylated G-CSF in mobilization are often used (3). The pegylated long acting form of G-CSF (peg- filgrastim) showed similar kinetics of mobilization Current stem cell mobilization regimens as filgrastim. A study in healthy donors report- ed suboptimal mobilization with a dose of 6 mg GCSF-based mobilization regimens but satisfactory yield with 12 mg (8). Such dose G-CSF with or without myelosuppressive che- dependence was not seen when pegfilgrastim was motherapy has been the most commonly used used with cyclophosphamide. Pegfilgrastim has the mobilization protocol since the 1990s. When used advantages of an earlier start of apheresis, reduc- alone, in both autologous and allogeneic trans- tion in the number of apheresis procedures and a 106 XXXIX. Ulusal Hematoloji Kongresi reduced number of injections in comparison with (1) insufficient number of HSCs because of HSC unconjugated G-CSF (9) but it is more costly. intrinsic factors Lenograstim compared with Filgrastim in (2) insufficient HSC number because of low stem cell mobilisation number or defective niches Lenograstim is a glycosylated form of G-CSF, (3) inadequate number or response of effector/ whereas filgrastim is nonglycosylated. Several pro- supporter cells such as BM macrophages or β-ad- spective studies have shown higher mobilization renergic nerves. yield with lenograstim. In contrast to healthy The following major criteria are proposed by the donors CD34+ cell yield appears similar in patients Italian GITMO working group as the definition of receiving either lenograstim or filgrastim after che- a poor mobilizer: (1) after adequate mobilization motherapy (10). (G-CSF 10 μg/kg if used alone or ≥5 μg/kg after chemotherapy) circulating CD34(+) cell peak is Stem cell factor in mobilization <20/μL up to 6 days after mobilization with G-CSF Stem Cell Factor (SCF (Ancestim)) exists as or up to 20 days after chemotherapy and G-CSF or a soluble form as well as a surface molecule on (2) they yielded <2.0 × 10(6) CD34(+) cells per kg in BM stromal cells. It binds to c-kit on HSCs and ≤3 apheresis (15). modulates proliferation and adhesion. As a single agent SCF has limited efficacy in HSC mobilization; Effects of underlying disease on mobilization of stem cells however, synergy between SCF and G-CSF exists. SCF at 20 μg/kg subcutaneously is started 4 days BM involvement by disease is associated with before the start of G-CSF and continued with the poor yields (16). There may be reduced HSC num- G-CSF until the end of apheresis. In failed mobiliz- bers partly related to the impairment of healthy ers SCF plus G-CSF with or without chemotherapy niches by malignant cells in the BM or direct com- enables adequate mobilization in 50% of patients petition between HSCs and malignant cells for a (11). In prior fludarabine-exposed patients SCF limited number of niches. with high-dose G-CSF resulted in a 63% success rate, almost doubling that in historical controls Effect of prior treatment on mobilization of that used G-CSF alone (12). stem cells Mobilization failure in autologous donors cor- GM-CSF in stem cell mobilization relates with the number of previous treatments GM-CSF is not more effective than G-CSF alone with chemotherapy. Most cytotoxic treatments and (13) and there is no synergy with G-CSF. Its use is molecules used in targeted therapies can have del- limited by dose-related toxicities. GM-CSF is rarely eterious effects on HSCs and the niches in which used in clinical practice. they reside. However, DNA cross-link agents such as melphalan or carmustine, and purine analogs Plerixafor in stem cell mobilization such as fludarabine are associated with a very high risk of mobilization failure. Cytotoxic drugs that do Plerixafor is a CXCR4 antagonist. It reduces the not specifically target cell progressing through the binding and chemotaxis of HSCs to the BM stro- S phase of the cell cycle (eg, anthracyclines, cis- ma. It is used at 240 μg/m2 subcutaneously the platin, fludarabine, carmustine, melphalan) could evening before the scheduled apheresis because potentially kill quiescent HSCs and niche cells, it generates peak CD34+ levels 6-9 hours after thereby reducing the HSC reserve. Fludarabine administration (14). It synergises with G-CSF and itself is toxic both to hematopoietic progenitors and chemotherapy. Plerixafor is the latest addition to to the niche. Alkylating agents such as chlorambu- the list of mobilizing agents and the first driven by cil given in a continuous manner may also be toxic understanding how mobilization occurs. on HSCs. Highly intensive, dose-dense regimens such as the hyper-CVAD (hyperfractionated cyclo- Risk factors for failure of mobilization of phosphamide, vincristine, doxorubicin, and dexa- stem cells methasone with methotrexate and cytarabine) reg- Poor mobilization may be inherent to a particu- imen are associated with a high risk of mobilization lar genetic combination specific to a person. It can failure beyond the first 2-4 cycles of therapy (17). also be acquired as a consequence of aging, prior Lenalidomide is associated with poor mobilization, treatments or disease. The possible defects could particularly after > 4 cycles of treatment. Lenalido- be at one or more of three levels: mide may suppress HSC motility similar to the way 23-26 Ekim 2013, Antalya 107 it reduces the motility of marrow endothelial cells for mobilization. For patients undergoing exten- in multiple myeloma. The antiangiogenic effect sive field radiotherapy, pre-treatment harvesting of Lenalidomide could also impair mobilization. should be considered if autologous transplantation Cyclophosphamide and GCSF based mobilization is a potential treatment option . is recommended for patients previously exposed to Lenalidomide (18). Long-term administration of Optimising apheresis for beter mobilization imatinib has been associated with reduced bone The peripheral blood CD34+ cell count is the turnover, which could affect HSC niche function best predictor of apheresis yield (24), and the use (19). Yields were improved if the patients temporar- of CD34+ cell counts to guide apheresis reduces ily withheld imatinib for 3 weeks prior to collection costs.If the circulating CD34+ cell count is ≥ 20/ (20). Prior radiotherapy to significant amounts of μL, 94% of collections performed the following day red marrow is associated with mobilization failure, would be expected to yield ≥ 2.0 × 106 CD34+ cells/ probably because of combined direct HSC toxicity, kg (24). In general terms if the CD34+ cell count is niche toxicity, and toxicity to the niche-supporting < 5/μL, the yield will be poor; therefore, apheresis cells (21). not warranted. Larger volume apheresis (process- ing ≥ 3 times the blood volume instead of 2 times) Effect of age on mobilization of stem cells results in higher HSC yields and may reduce the Poor mobilization is often noted in patients > number of sessions in some cases. 60 years of age (21). Firstly, there is an age-relat- ed “senescence” of actual HSCs because of pro- Improving stem cell collection in gressive telomere shortening. Secondly, there is a mobilization failure reduction in the HSC reserve caused by decreased Approaches to failed mobilization after conven- niche function with depletion of mesenchymal tional regimens include increased doses of G-CSF stem cells and osteoprogenitors.
Load more

Recommended publications
  • Therapeutic Class Overview Colony Stimulating Factors
    Therapeutic Class Overview Colony Stimulating Factors Therapeutic Class Overview/Summary: This review will focus on the granulocyte colony stimulating factors (G-CSFs) and granulocyte- macrophage colony stimulating factors (GM-CSFs).1-5 Colony-stimulating factors (CSFs) fall under the naturally occurring glycoprotein cytokines, one of the main groups of immunomodulators.6 In general, these proteins are vital to the proliferation and differentiation of hematopoietic progenitor cells.6-8 The G- CSFs commercially available in the United States include pegfilgrastim (Neulasta®), filgrastim (Neupogen®), filgrastim-sndz (Zarxio®), and tbo-filgrastim (Granix®). While filgrastim-sndz and tbo- filgrastim are the same recombinant human G-CSF as filgrastim, only filgrastim-sndz is considered a biosimilar drug as it was approved through the biosimilar pathway. At the time tbo-filgrastim was approved, a regulatory pathway for biosimilar drugs had not yet been established in the United States and tbo-filgrastim was filed under its own Biologic License Application.9 Only one GM-CSF is currently available, sargramostim (Leukine). These agents are Food and Drug Administration (FDA)-approved for a variety of conditions relating to neutropenia or for the collection of hematopoietic progenitor cells for collection by leukapheresis.1-5 Due to the pathway taken, tbo-filgrastim does not share all of the same indications as filgrastim and these two products are not interchangeable. It is important to note that although filgrastim-sndz is a biosimilar product, and it was approved with all the same indications as filgrastim at the time, filgrastim has since received FDA-approval for an additional indication that filgrastim-sndz does not have, to increase survival in patients with acute exposure to myelosuppressive doses of radiation.1-3A complete list of indications for each agent can be found in Table 1.
    [Show full text]
  • Ontario Drug Benefit Formulary Edition 43
    Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Drug Programs Policy and Strategy Branch Ontario Public Drug Programs Ministry of Health and Long-Term Care Effective February 28, 2018 Visit Formulary Downloads: Edition 43 Table of Contents Part I Introduction ....................................................................................................... I.1 Part II Preamble .......................................................................................................... II.1 Part III-A Benefits List ........................................................................................... III-A.1 Part III-B Off-Formulary Interchangeable Drugs (OFI) ........................................ III-B.1 Part IV Section Currently Not In Use ......................................................................... IV Part V Index of Pharmacologic-Therapeutic Classification .................................... V.1 Part VI-A Facilitated Access - HIV/AIDS .............................................................. VI-A.1 Part VI-B Facilitated Access - Palliative Care ..................................................... VI-B.1 Part VI-C Temporary Facilitated Access - Rheumatology ................................. VI-C.1 Part VII Trillium Drug Program ................................................................................ VII.1 Part VIII Exceptional Access Program (EAP) ........................................................ VIII.1 Part IX-A Nutrition Products ................................................................................
    [Show full text]
  • The Act of Controlling Adult Stem Cell Dynamics: Insights from Animal Models
    biomolecules Review The Act of Controlling Adult Stem Cell Dynamics: Insights from Animal Models Meera Krishnan 1, Sahil Kumar 1, Luis Johnson Kangale 2,3 , Eric Ghigo 3,4 and Prasad Abnave 1,* 1 Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd Milestone, Gurgaon-Faridabad Ex-pressway, Faridabad 121001, India; [email protected] (M.K.); [email protected] (S.K.) 2 IRD, AP-HM, SSA, VITROME, Aix-Marseille University, 13385 Marseille, France; [email protected] 3 Institut Hospitalo Universitaire Méditerranée Infection, 13385 Marseille, France; [email protected] 4 TechnoJouvence, 13385 Marseille, France * Correspondence: [email protected] Abstract: Adult stem cells (ASCs) are the undifferentiated cells that possess self-renewal and differ- entiation abilities. They are present in all major organ systems of the body and are uniquely reserved there during development for tissue maintenance during homeostasis, injury, and infection. They do so by promptly modulating the dynamics of proliferation, differentiation, survival, and migration. Any imbalance in these processes may result in regeneration failure or developing cancer. Hence, the dynamics of these various behaviors of ASCs need to always be precisely controlled. Several genetic and epigenetic factors have been demonstrated to be involved in tightly regulating the proliferation, differentiation, and self-renewal of ASCs. Understanding these mechanisms is of great importance, given the role of stem cells in regenerative medicine. Investigations on various animal models have played a significant part in enriching our knowledge and giving In Vivo in-sight into such ASCs regulatory mechanisms. In this review, we have discussed the recent In Vivo studies demonstrating the role of various genetic factors in regulating dynamics of different ASCs viz.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Comparison Between Filgrastim and Lenograstim Plus Chemotherapy For
    Bone Marrow Transplantation (2010) 45, 277–281 & 2010 Macmillan Publishers Limited All rights reserved 0268-3369/10 $32.00 www.nature.com/bmt ORIGINAL ARTICLE Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs R Ria, T Gasparre, G Mangialardi, A Bruno, G Iodice, A Vacca and F Dammacco Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy Recombinant human (rHu) G-CSF has been widely used during transplantation.4 However, the use of G-CSF after to treat neutropenia and mobilize PBPCs for their autologous PBPC transplantation has been queried, as its autologous and allogeneic transplantation. It shortens further reduction in time to a safe neutrophil count5,6 does neutropenia and thus reduces the frequency of neutropenic not always imply fewer significant clinical events, such as fever. We compared the efficiency of glycosylated rHu infections, length of hospitalization, extrahematological and non-glycosylated Hu G-CSF in mobilizing hemato- toxicities or mortality.7,8 Even so, the ASCO guidelines still poietic progenitor cells (HPCs). In total, 86 patients were recommend the use of growth factors after autologous consecutively enrolled for mobilization with CY plus either PBPC transplantation.9 glycosylated or non-glycosylated G-CSF, and under- G-CSF induces the proliferation and differentiation of went leukapheresis. The HPC content of each collection, myeloid precursor cells, and also provides a functional toxicity, days of leukapheresis needed to reach the activity that influences chemotaxis, respiratory burst and minimum HPC target and days to recover WBC (X500 Ag expression of neutrophils.
    [Show full text]
  • G-CSF Protects Motoneurons Against Axotomy-Induced Apoptotic Death In
    Henriques et al. BMC Neuroscience 2010, 11:25 http://www.biomedcentral.com/1471-2202/11/25 RESEARCH ARTICLE Open Access G-CSF protects motoneurons against axotomy- induced apoptotic death in neonatal mice Alexandre Henriques1,2,3, Claudia Pitzer1*, Luc Dupuis2,3, Armin Schneider1* Abstract Background: Granulocyte colony stimulating factor (G-CSF) is a growth factor essential for generation of neutrophilic granulocytes. Apart from this hematopoietic function, we have recently uncovered potent neuroprotective and regenerative properties of G-CSF in the central nervous system (CNS). The G-CSF receptor and G-CSF itself are expressed in a motoneurons, G-CSF protects motoneurons, and improves outcome in the SOD1(G93A) transgenic mouse model for amyotrophic lateral sclerosis (ALS). In vitro, G-CSF acts anti- apoptotically on motoneuronal cells. Due to the pleiotrophic effects of G-CSF and the complexity of the SOD1 transgenic ALS models it was however not possible to clearly distinguish between directly mediated anti- apoptotic and indirectly protective effects on motoneurons. Here we studied whether G-CSF is able to protect motoneurons from purely apoptotic cell death induced by a monocausal paradigm, neonatal sciatic nerve axotomy. Results: We performed sciatic nerve axotomy in neonatal mice overexpressing G-CSF in the CNS and found that G-CSF transgenic mice displayed significantly higher numbers of surviving lumbar motoneurons 4 days following axotomy than their littermate controls. Also, surviving motoneurons in G-CSF overexpressing animals were larger, suggesting additional trophic effects of this growth factor. Conclusions: In this model of pure apoptotic cell death the protective effects of G-CSF indicate direct actions of G-CSF on motoneurons in vivo.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • ©Ferrata Storti Foundation
    Stem Cell Transplantation • Research Paper Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors Frank Kroschinsky Background and Objectives. Short-term treatment with granulocyte colony-stimulating Kristina Hölig factor (G-CSF) has been established as the standard regimen for mobilizing allogeneic Kirsten Poppe-Thiede peripheral blood progenitor cells (PBPC) from healthy donors. The pegylated form of fil- Kristin Zimmer grastim (pegfilgrastim) has a longer elimination half-life because of decreased serum Rainer Ordemann clearance and might be a convenient alternative for stem cell mobilization. Matthias Blechschmidt Uta Oelschlaegel Design and Methods. Twenty-five family (n=15) or unrelated (n=10) healthy donors received a single-dose of 12 mg pegfilgrastim for mobilization of allogeneic PBPC. Martin Bornhauser + Gabi Rall Donors with inadequate mobilization (blood CD34 cells ≤5/µL on day 3 or ≤20/µL on Claudia Rutt day 4) were given additional daily doses of 10 µg/kg conventional filgrastim. Gerhard Ehninger Leukapheresis was planned to start on day 5. Results. All harvests were completed successfully. In 20 out of 25 donors (80 %) only a single apheresis was necessary. Additional non-pegylated filgrastim had to be given to only one 74-year old family donor. The maximum concentration of circulating CD34+ + cells occurred on day 5 (median 67/µL, range 10-385/µL). The median yield of CD34 cells was 9.3 (range 3.2-39.1) 106/kg of the recipient´s body weight. The median × 8 number of T cells in the apheresis products was 3.9 (range 2.7-10.8)×10 /kg.
    [Show full text]
  • WO 2016/174183 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/174183 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: dreas; Pistoriusstr. 7, 13086 Berlin (DE). NEUHAUS, Ro¬ Λ 61Κ 31/4439 (2006.01) A61K 31/519 (2006.01) land; Lauenburger Str. 28, 12157 Berlin (DE). A61K 31/454 (2006.01) A61K 31/5377 (2006.01) (74) Agent: BIP PATENTS; c/o Bayer Intellectual Property A61K 31/496 (2006.01) A61K 31/55 (2006.01) GmbH, Alfred-Nobel-Str. 10, 40789 Monheim am Rhein A61K 31/497 (2006.01) C07D 401/12 (2006.01) (DE). A61K 31/4985 (2006.01) A61P 35/02 (2006.01) A61K 31/505 (2006.01) A61P 35/00 (2006.01) (81) Designated States (unless otherwise indicated, for every A61K 31/506 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/EP2016/059576 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 29 April 2016 (29.04.2016) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Human G-CSF ELISA Kit (ARG80143)
    Product datasheet [email protected] ARG80143 Package: 96 wells Human G-CSF ELISA Kit Store at: 4°C Component Cat. No. Component Name Package Temp ARG80143-001 Antibody-coated 8 X 12 strips 4°C. Unused strips microplate should be sealed tightly in the air-tight pouch. ARG80143-002 Standard 3 X 2 ng/vial 4°C (Lyophilized) ARG80143-003 Standard diluent 20 ml 4°C buffer ARG80143-004 Antibody conjugate 400 µl 4°C concentrate ARG80143-005 Antibody diluent 16 ml 4°C buffer ARG80143-006 HRP-Streptavidin 400 µl 4°C (Protect from concentrate light) ARG80143-007 HRP-Streptavidin 16 ml 4°C diluent buffer ARG80143-008 20X Wash buffer 50 ml 4°C ARG80143-009 TMB substrate 12ml 4°C (Protect from light) ARG80143-010 STOP solution 12ml 4°C ARG80143-011 Plate sealer 4 strips Room temperature Summary Product Description ARG80143 Human G-CSF ELISA Kit is an Enzyme Immunoassay kit for the quantification of Human G-CSF in Serum, Plasma, Cell culture supernatants. Tested Reactivity Hu Tested Application ELISA Specificity No significant cross-reactivity or interference with Human CT-1,IL-11,OSM,CNTF,HGF,M-CSF；mouse IL-6；rat IL-6,CNTF Target Name G-CSF Conjugation HRP Conjugation Note Substrate: TMB and read at 450 nm Sensitivity 15 pg/ml Sample Type Serum, Plasma, Cell culture supernatants Standard Range 31.25 - 2000 pg/ml www.arigobio.com 1/3 Sample Volume 100 µl Precision CV: Alternate Names Granulocyte colony-stimulating factor; Lenograstim; C17orf33; GCSF; G-CSF; Filgrastim; Pluripoietin; CSF3OS Application Instructions Assay Time 4 hours Properties Form 96 well Storage instruction Store the kit at 2-8°C.
    [Show full text]
  • STEMGEN® (Ancestim) Product Information Page 1 of 12
    STEMGEN® (ancestim) Product Information Page 1 of 12 NAME OF THE DRUG Ancestim is a human stem cell factor (SCF), produced by recombinant DNA technology. STEMGEN® is the Amgen Inc. trademark for ancestim (recombinant methionyl human stem cell factor, r-metHuSCF). DESCRIPTION STEMGEN® is a 166 amino acid protein produced by Escherichia coli (E coli) bacteria into which a gene has been inserted for soluble human stem cell factor. STEMGEN® has a monomeric molecular weight of approximately 18,500 daltons and normally exists as a noncovalently associated dimer. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine retained after expression in E coli. Because STEMGEN® is produced in E coli, the product is nonglycosylated. STEMGEN® is a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection. Each single-use vial of STEMGEN® contains 1.875 mg of ancestim at a specific activity of 0.84 to 1.8 x 106 U/mg (as measured by a cell mitogenesis assay). Vials of STEMGEN® are reconstituted with 1.2 mL of sterile Water for Injection to yield an ancestim concentration of 1500 µg/mL. Reconstituted STEMGEN® is a sterile aqueous solution containing 4.5% mannitol and 0.5% sucrose buffered at pH 6.0 with 5 mM glutamic acid and 10 mM histidine. PHARMACOLOGY Pharmacokinetics General The pharmacokinetics of STEMGEN® are dose linear in the range of 5 to 30 µg/kg in both healthy volunteers and cancer patients.
    [Show full text]
  • NEUPOGEN® (Filgrastim) DESCRIPTION Filgrastim Is a Human Granulocyte Colony-Stimulating Factor (G-CSF)‚ Produced by Recombinant DNA Technology
    NEUPOGEN® (Filgrastim) DESCRIPTION Filgrastim is a human granulocyte colony-stimulating factor (G-CSF)‚ produced by recombinant DNA technology. NEUPOGEN® is the Amgen Inc. trademark for filgrastim‚ which has been selected as the name for recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF). NEUPOGEN® is a 175 amino acid protein manufactured by recombinant DNA technology.1 NEUPOGEN® is produced by Escherichia coli (E coli) bacteria into which has been inserted the human granulocyte colony-stimulating factor gene. NEUPOGEN® has a molecular weight of 18‚800 daltons. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis‚ except for the addition of an N-terminal methionine necessary for expression in E coli. Because NEUPOGEN® is produced in E coli‚ the product is nonglycosylated and thus differs from G-CSF isolated from a human cell. NEUPOGEN is a sterile‚ clear‚ colorless‚ preservative-free liquid for parenteral administration containing filgrastim at a specific activity of 1.0 ± 0.6 x 108 U/mg (as measured by a cell mitogenesis assay). The product is available in single-use vials and prefilled syringes. The single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL, respectively. The single-use prefilled syringes contain either 300 mcg or 480 mcg filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. See table below for product composition of each single-use vial or prefilled syringe. 300 mcg/ 480 mcg/ 300 mcg/ 480 mcg/ 1.0 mL Vial 1.6 mL Vial 0.5 mL Syringe 0.8 mL Syringe filgrastim 300 mcg 480 mcg 300 mcg 480 mcg Acetate 0.59 mg 0.94 mg 0.295 mg 0.472 mg Sorbitol 50.0 mg 80.0 mg 25.0 mg 40.0 mg Polysorbate 80 0.04 mg 0.064 mg 0.02 mg 0.032 mg Sodium 0.035 mg 0.056 mg 0.0175 mg 0.028 mg Water for Injection USP q.s.
    [Show full text]